AGP Executive Report
Last update: 10 hours agoImaging Expansion: RadNet agreed to acquire teleradiology provider Onrad for $350 million upfront, plus shares and potential milestones, adding a new business as hospitals seek help with radiologist staffing. Cancer R&D: Astellas will pay Audax Bio $285 million upfront, with the deal potentially reaching $1.34 billion, for an early-stage immunotherapy designed to concentrate immune activity in tumors. A Phase 1 trial is planned for 2027. Medicaid Coverage: New work requirements starting in January could put one in five Medicaid expansion adults at risk of losing coverage. Many enrollees are unaware of the rules, and inconsistent work hours could complicate compliance. Drug Prices: India’s Supreme Court challenged steep hospital markups and the government’s reluctance to expand price controls, saying industry growth cannot outweigh patients’ access to medicines. Diabetes Trial: Lilly said its triple-hormone drug outperformed Ozempic in a diabetes study, intensifying competition in the treatment market. GSK Results: Vaccine sales fell 2% in the third quarter, led by declines for Shingrix and Arexvy, while overall revenue rose 5% on stronger specialty medicine and HIV sales.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[FDA pilot aims to shorten residue method requirements for food-animal drugs]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/29858773-952976091-04e668cace8fd6625d093671d4e02f5b3a3fb1e1-7360x4912-200x134.jpeg)
